• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Golimumab effective at preserving insulin production in type 1 diabetes

bySamuel ChanandDeepti Shroff Karhade
November 25, 2020
in Endocrinology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized, double-blind, phase two trial, the use of golimumab led to more C-peptide production, indicative of improved endogenous function, compared to placebo in new type 1 diabetics.

2. Patients that received golimumab used less exogenous insulin compared to placebo.

Evidence Rating Level: 2 (Good)

Study Rundown: TNF-α has been implicated in the pathogenesis of type 1 diabetes. Golimumab is an antibody directed against TNF-α that has been approved for various other autoimmune diseases such as ulcerative colitis and rheumatoid arthritis. This was a randomized, double-blind, placebo-controlled trial of newly diagnosed type 1 diabetics treated with golimumab. The 4-hour C-peptide area under concentration-time curve (AUC) measured at 52 weeks was higher in the golimumab treated group compared to placebo which indicated a higher endogenous insulin production. At 52 weeks, there was a greater increase in insulin use in the placebo group. The trial was limited by the smaller number of participants. Furthermore, clinically relevant endpoints such as reductions in hypoglycemic events and quality of life were not investigated. Understandably given the short duration of the trial, diabetic complications such as retinopathy, neuropathy and nephropathy were not investigated but this will be important information to justify changes in practice in the future. Overall, the authors have demonstrated promising C-peptide responses with the use of golimumab which is indicative of improved beta-cell health but clinically relevant endpoints will be important investigational endpoints in further studies.

Click here to read the study in the NEJM

Relevant Reading: Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

In-Depth [randomized controlled trial]: This was a phase two, double-blind, placebo-controlled, randomized trial examining the the use of golimumab to preserve beta cell function in 84 persons aged 6-21 who were newly diagnosed with type 1 diabetes (randomized within 100 days of diagnosis). The primary endpoint was assessed at 52 weeks. The mean 4-hour C-peptide AUC was higher in the golimumab group (0.64±0.42 vs. 0.43±0.39 pmol per milliliter; p <0.001). The least-squares mean change from baseline for insulin use was lower in the treatment group (0.07 U vs. 0.24 U per kilogram per day, p = 0.001) while HbA1c glycemic targets were similar (7.3±1.5% vs. 7.6±1.2%). The Hodges–Lehmann estimate of the median difference between treatment and placebo for fasting proinsulin to C-peptide was 0.124 (95% CI, 0.064 to 0.184), which indicated the treatment group may have had better beta-cell health. Infections were found in 71% of the treatment group, and 61% of the placebo group; a baseline decrease in neutrophil was higher in the treatment group (29% vs. 19%) where 4 patients had grade 3-4 neutropenia in the golimumab group. Hypoglycemia was higher in the golimumab group (23%) compared to the placebo (7%).

RELATED REPORTS

Light exposure during sleep may alter glucose metabolism and impair cardiometabolic function

Enteric administration of recombinant human insulin to preterm infants is safe and effective

Wellness Check: Nutrition

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: golimumabinsulintumor necrosis factor (TNF)type 1 diabetes
Previous Post

No mortality benefit found for in-home glucose-lowering medications among those with COVID-19

Next Post

#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

RelatedReports

Filtered-sunlight may effectively treat neonatal jaundice in resource-poor settings
Cardiology

Light exposure during sleep may alter glucose metabolism and impair cardiometabolic function

April 19, 2022
Neonatal neuroimaging with strong negative predictive value for developmental outcomes: The NEURO study
Pediatrics

Enteric administration of recombinant human insulin to preterm infants is safe and effective

April 4, 2022
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

March 31, 2022
Racial, ethnic differences in outcomes of extremely preterm infants decreasing but persistent
Endocrinology

Enteral insulin reduces the duration of feeding intolerance in preterm infants

March 4, 2022
Next Post
#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

Fewer work hours linked to greater likelihood of continued breastfeeding

Association between maternal breastfeeding satisfaction and postpartum depression

Initial data on the viability of SARS-CoV-2 in aerosol and on surfaces

Lessons from a Covid-19 outbreak on a naval aircraft carrier

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.